Incyte Corporation Company Profile (NASDAQ:INCY)

Incyte Corporation trades on the NASDAQ under the ticker symbol "INCY."

Incyte Corporation (NASDAQ:INCY) issued its earnings results on Thursday, May, 4th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.97) by $0.01. The business earned $384.08 million during the quarter, compared to analysts' expectations of $359.19 million. Incyte Corporation had a negative return on equity of 20.09% and a negative net margin of 8.72%. Incyte Corporation's quarterly revenue was up 45.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.12 EPS. View Incyte Corporation's Earnings History.

21 brokers have issued 12-month price targets for Incyte Corporation's shares. Their predictions range from $98.00 to $185.00. On average, they expect Incyte Corporation's share price to reach $143.33 in the next year. View Analyst Ratings for Incyte Corporation.

Here are some recent quotes from research analysts about Incyte Corporation stock:

• 1. Cowen and Company analysts commented, "Over the weekend Incyte presented multiple datasets from a Phase I/II trial of." (6/5/2017)
• 2. According to Zacks Investment Research, "Incyte’s first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations. The growth in Jakafi sales is driven by patient demand and should boost revenues. While most of the demand is due to a larger established patient base in myelofibrosis, polycythemia vera is also expected to be a major long-term driver of Jakafi growth. This is owing to the larger potential patient population and the possibility for longer duration of treatment. The company exited the first quarter with approximately 10,000 patients being treated with Jakafi. However, Incyte’s dependence on a single product, Jakafi, for growth is concerning. Moreover, the FDA has issued a CRL to new drug application (NDA) for baricitinib asking for additional information. The delay in approval is disappointing. Moreover, loss estimates for 2017 have widened significantly following the first-quarter results." (5/23/2017)
• 3. Instinet analysts commented, "Incyte has been incrementally expanding the opportunity for its JAK franchise in oncology and autoimmune. We anticipate near-term upside from novel JAK combos, formulations, and applications in oncology and autoimmune disease. These under-recognized programs represent $25/sh of our target price and, in our view, offer lower-risk opportunities vs. epacadostat." (3/1/2017)

Incyte Corporation saw a decrease in short interest in June. As of June 15th, there was short interest totalling 3,023,910 shares, a decrease of 27.7% from the May 31st total of 4,182,735 shares. Based on an average daily volume of 1,929,555 shares, the short-interest ratio is presently 1.6 days. Currently, 1.5% of the company's shares are short sold.

Some companies that are related to Incyte Corporation include Quintiles Transitional Holdings (Q), Alkermes PLC (ALKS), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), ICON PLC (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Exact Sciences Corporation (EXAS), Galapagos NV (GLPG), ACADIA Pharmaceuticals (ACAD), WuXi PharmaTech (Cayman) (WX), Puma Biotechnology (PBYI) and INC Research Holdings (INCR).

Incyte Corporation's management team includes the folowing people:

• Herve Hoppenot, Chairman of the Board, President, Chief Executive Officer
• David W. Gryska, Chief Financial Officer, Executive Vice President
• Reid M. Huber, Executive Vice President, Chief Scientific Officer
• Eric H. Siegel, Executive Vice President, General Counsel
• Paula J. Swain, Executive Vice President - Human Resources
• Barry P. Flannelly, Executive Vice President and General Manager , US
• Vijay Iyengar, Executive Vice President, Global Strategy and Corporate Development`
• Wenqing Yao Ph.D., Executive Vice President, Head of Discovery Chemistry
• Steven H. Stein M.D., Vice President and Chief Medical Officer
• Julian C. Baker, Lead Independent Director

Incyte Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (16.80%), Vanguard Group Inc. (8.14%), State Street Corp (3.70%), BB Biotech AG (1.84%), FMR LLC (1.57%) and Brown Capital Management LLC (0.99%). Company insiders that own Incyte Corporation stock include Barry P Flannelly, David W Gryska, Eric H Siegel, Jean Jacques Bienaime, Julian Baker, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Richard S Levy, Steven H Stein and Yao Wenqing. View Institutional Ownership Trends for Incyte Corporation.

Incyte Corporation's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Nicholas Investment Partners LP, Marshall Wace LLP, Brown Capital Management LLC, Point72 Asset Management L.P., BB Biotech AG, Cibc World Markets Corp and Tekla Capital Management LLC. Company insiders that have sold Incyte Corporation stock in the last year include Barry P Flannelly, David W Gryska, Eric H Siegel, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber and Steven H Stein. View Insider Buying and Selling for Incyte Corporation.

Incyte Corporation's stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Victory Capital Management Inc., Geode Capital Management LLC, Morgan Stanley, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P. and UBS Asset Management Americas Inc.. Company insiders that have bought Incyte Corporation stock in the last two years include Jean Jacques Bienaime and Julian Baker. View Insider Buying and Selling for Incyte Corporation.

Shares of Incyte Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Incyte Corporation stock can currently be purchased for approximately $134.67.